胸腺肽α1联合痰热清注射液治疗卫生保健相关性肺炎的临床疗效观察  

The clinical efficacy ovservation of thymosin α1 combined with Tanreqing Injection in treatment of health-care-associated pneumonia

作　　者：凌云 LING Yun(Department of Emergency ,Shanghai Baoshan District Combine Traditional Chinese and Western Medicine Hospital, Shanghai 201999, China)

机构地区：[1]上海市宝山区中西医结合医院急诊科,201900

出　　处：《检验医学与临床》2017年第A01期76-78,共3页Laboratory Medicine and Clinic

摘　　要：目的 探讨胸腺肽α1联合痰热清注射液治疗卫生保健相关性肺炎的临床疗效.方法 选取本院急诊观察室收治的64例卫生保健相关性肺炎患者,随机分为对照组和治疗组,各32例;对照组采取常规内科治疗,治疗组在常规治疗基础上加用胸腺肽α1联合痰热清注射液,治疗1周后观察临床疗效、白细胞计数（WBC）、降钙素原（PCT）及CD64指数,观察治疗组有无药物不良反应.结果 治疗组患者临床有效率93.6%,优于对照组的75.0%,差异有统计学意义（P〈0.05）.治疗后WBC、PCT、CD64指数下降水平优于对照组[WBC：（8.52±2.04）×109/L比（10.59±2.60）×109/L,PCT：（3.40±2.42）ng/mL比（4.68±2.92）ng/mL,CD64指数：（22.78±7.15）%比（26.06±9.48）%],差异均有统计学意义（均P〈0.05）.治疗组未发现药物不良反应.结论 胸腺肽α1联合痰热清注射液治疗卫生保健相关性肺炎的临床效果显著,值得临床推广使用.Objective To discuss the clinical efficacy of thymosin α1 combined with Tanreqing Injection in treatment of health-care-associated pneumonia.Methods 64 patients with health-care-associated pneumonia in the emergency observation ward were chosen and randomly divided into the control group and treatment group.32 patients in the control group were given conventional treatment,32 patients in the treatment group were given thymosin α1 and Tanreqing Injection in the base of conventional treatment.The clinical efficacy,the level of white blood cell count（WBC）,procalcitonin（PCT）,CD64 index and the adverse drug reaction in treatment group were observed after 1 week treatment.Results The clinical effective rate of the treatment group was 93.6%,which is higher than that of the control group（75.0%）,the difference was statistically significant（P〈0.05）.The WBC,PCT and CD64 index were superior to the control group[WBC：（8.52±2.04）×109/L vs（10.59±2.60）×109/L,PCT：（3.40±2.42） ng/mL vs（4.68±2.92）ng/mL,CD64 index：（22.78±7.15）% vs（26.06±9.48）%],the difference was statistically significant（all P〈0.05）.The adverse drug reaction was not appear in treatment group in the process of treatment.Conclusion Thymosin α1 combined with Tanreqing Injection is worthy of application in treatment of health-care-associated pneumonia,because of its superior clinical therapeutic effect.

关 键 词：痰热清 胸腺肽Α1 卫生保健相关性肺炎 

分 类 号：R259.631[医药卫生—中西医结合]